Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103380 | 0.82 | — | — | |
| SCHEMBL17103385 | 0.82 | — | — | |
| SCHEMBL15415966 | 0.82 | — | — | |
| SCHEMBL17103348 | 0.79 | — | — | |
| SCHEMBL17654280 | 0.73 | — | — | |
| SCHEMBL8303074 | 0.70 | KDM1A (0.37) | NISCHKIF11NOS3NOS2 | |
| SCHEMBL17654264 | 0.70 | — | — | |
| SCHEMBL895697 | 0.69 | CA2 (0.36) | TRPV4LOXL2LOXNOS3NOS2 | |
| SCHEMBL7701584 | 0.67 | L3MBTL1 (0.39) | ALDH1A1 | |
| SCHEMBL450929 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149234-A1 | PARP7 INHIBITORS AND USES THEREOF | Angel Pharmaceutical Co., Ltd. (CN) | 2024-07-18 | — | — | WO | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| EP-4031544-B1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR AND SULFOXIMINE CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2024-02-28 | — | — | EP | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | claimed |
| CN-117157291-A | Heterocyclic derivatives as P2X7 receptor antagonists | 布雷耶疗法有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023227734-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-30 | — | — | WO | claimed |
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | claimed |
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-11-09 | — | — | US | claimed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | claimed |
| EP-0973395-A4 | DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM | ISK AMERICAS INC (US) | 2001-10-04 | — | — | EP | claimed |
| US-6121201-A | HETEROARYL SUBSTITUTED HALO-PYRAZOLE SUBSTITUTED DIARYL ETHERS OR THIOETHERS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2000-09-19 | — | — | US | claimed |
| EP-0973395-A1 | DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM | ISK Americas Incorporated (US) | 2000-01-26 | — | — | EP | claimed |
| US-5977110-A | Substituted cyclohexylamines as central nervous systems agents | WARNER-LAMBERT COMPANY (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998041093-A1 | DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM | ISK AMERICAS INCORPORATED (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0586393-B1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | claimed |
| US-5439910-A | For applying to plants, seeds or soils | ZENECA LIMITED (GB) | 1995-08-08 | — | — | US | claimed |
| US-5401763-A | Derivatives of arylacetic esters displaying high fungicidal activity | Ministero Dell `Universita` e Della Ricerca Scientifica e Technologica (IT) | 1995-03-28 | — | — | US | claimed |
| EP-0611760-A1 | Derivatives of arylacetic esters displaying high fungicidal activity | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1994-08-24 | — | — | EP | claimed |
| US-5326767-A | α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1994-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | NISCH 590/4885KIF11 1940/4885TRPV4 2881/4885 |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | NISCH 2181/4885KIF11 4359/4885TRPV4 1071/4885 |
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | NISCH 4420/4885KIF11 4130/4885TRPV4 2214/4885 |
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | P2RX3, P2RX4, P2RX7 | NISCH 1228/4885KIF11 4708/4885TRPV4 26/4885 |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | P2RX7, P2RX3, P2RX1 | NISCH 3166/4885KIF11 4875/4885TRPV4 44/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | NISCH 590/4885KIF11 1940/4885TRPV4 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.